Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
Clinical trial NCT04016805 · TERMINATED
Trial details
- NCT number
- NCT04016805
- Sponsor
- TG Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-05
- Primary completion
- 2022-05-22
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.